半乳糖凝集素-3 与经皮冠状动脉介入治疗后首次心肌梗死后早期再梗死发生的相关性。
The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively.
机构信息
Department of Internal Diseases and Cardiological Rehabilitation .
出版信息
Biomarkers. 2013 Dec;18(8):655-9. doi: 10.3109/1354750X.2013.840801. Epub 2013 Oct 8.
CONTEXT
Galectin-3, as a biomarker of inflammation and fibrosis, has been reported to be associated with coronary artery disease.
OBJECTIVE
The study aimed to assess the relationship between galectin-3 levels and the occurrence of reinfarction early after myocardial infarction (MI).
METHODS
The study included 145 consecutive patients with first MI treated invasively. Serum galectin-3 was measured using VIDAS (bioMérieux, Marcy-l'Etoile, France).
RESULTS
The independent predictors of reinfarction in our group were as follows: female gender, elevated hs-C-reactive protein and galectin-3 levels (measured both at discharge).
CONCLUSIONS
Galectin-3 might be an additional useful biomarker in prediction for reinfarction early after first MI.
背景
半乳糖凝集素-3 作为炎症和纤维化的生物标志物，已被报道与冠状动脉疾病相关。
目的
本研究旨在评估半乳糖凝集素-3 水平与心肌梗死后早期再梗死发生的关系。
方法
本研究纳入了 145 例接受介入治疗的首次心肌梗死连续患者。使用 VIDAS（生物梅里埃，马西-勒泰奥勒，法国）检测血清半乳糖凝集素-3。
结果
在我们的研究人群中，再梗死的独立预测因素如下：女性、高 hs-C 反应蛋白和半乳糖凝集素-3 水平（均在出院时测量）。
结论
半乳糖凝集素-3 可能是预测首次心肌梗死后早期再梗死的另一个有用的生物标志物。
Zotero 插件